SCZD
MCID: SCH015
MIFTS: 77

Schizophrenia (SCZD) malady

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia

Aliases & Descriptions for Schizophrenia:

Name: Schizophrenia 54 54 54 38 12 24 25 66 29 13 52 41 42 14 69
Schizoaffective Disorder 54 12 66 52 14 69
Schizophrenia 12 54 13 69
Schizophrenia 9 66 29 69
Schizophrenia 6 29 69
Schizophrenia Susceptibility Locus Chromosome 1q-Related 66
Schizophrenia, Susceptibility to 13
Dementia Praecox 25
Schizophrenia-1 12
Schizophrenia 1 69
Sczd9 66
Sczd 66

Characteristics:

HPO:

32
schizophrenia:
Inheritance autosomal dominant inheritance heterogeneous


Classifications:



Summaries for Schizophrenia

MedlinePlus : 41 schizophrenia is a serious brain illness. people who have it may hear voices that aren't there. they may think other people are trying to hurt them. sometimes they don't make sense when they talk. the disorder makes it hard for them to keep a job or take care of themselves. symptoms of schizophrenia usually start between ages 16 and 30. men often develop symptoms at a younger age than women. people usually do not get schizophrenia after age 45. there are three types of symptoms: psychotic symptoms distort a person's thinking. these include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements. "negative" symptoms make it difficult to show emotions and to function normally. a person may seem depressed and withdrawn. cognitive symptoms affect the thought process. these include trouble using information, making decisions, and paying attention. no one is sure what causes schizophrenia. your genes, environment, and brain chemistry may play a role. there is no cure. medicine can help control many of the symptoms. you may need to try different medicines to see which works best. you should stay on your medicine for as long as your doctor recommends. additional treatments can help you deal with your illness from day to day. these include therapy, family education, rehabilitation, and skills training. nih: national institute of mental health

MalaCards based summary : Schizophrenia, also known as schizoaffective disorder, is related to personality disorder and hereditary multiple exostoses, and has symptoms including hypertelorism, frontal bossing and eeg abnormality. An important gene associated with Schizophrenia is DISC1 (Disrupted In Schizophrenia 1), and among its related pathways/superpathways is Monoamine GPCRs. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and behavior/neurological

Disease Ontology : 12 A psychotic disorder that is characterized by a disintegration of thought processes and of emotional responsiveness.

Genetics Home Reference : 25 Schizophrenia is a mental health disorder classified as a psychosis, which means that it affects a person's thinking, sense of self, and perceptions. The disorder typically appears during late adolescence or early adulthood.

OMIM : 54 Schizophrenia is a psychosis, a disorder of thought and sense of self. Although it affects emotions, it is... (181500) more...

UniProtKB/Swiss-Prot : 66 Schizophrenia: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

Wikipedia : 71 Schizophrenia is a mental disorder characterized by abnormal social behavior and failure to understand... more...

Related Diseases for Schizophrenia

Diseases in the Schizophrenia family:

Schizophrenia 17 Schizophrenia 16
Schizophrenia 10 Schizophrenia 4
Schizophrenia 15 Early-Onset Schizophrenia

Diseases related to Schizophrenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 328)
id Related Disease Score Top Affiliating Genes
1 personality disorder 31.4 COMT DISC1 DRD2 DRD3 DTNBP1 HTR2A
2 hereditary multiple exostoses 29.8 COMT DRD2 HTR2A
3 paranoid schizophrenia 12.5
4 schizophrenia 4 12.2
5 schizophrenia 17 12.1
6 schizophrenia 15 12.1
7 early-onset schizophrenia 12.1
8 schizophrenia susceptibility 18 12.1
9 childhood-onset schizophrenia 12.0
10 schizophrenia 10 11.8
11 schizophrenia 16 11.8
12 schizophrenia mental retardation deafness retinitis 11.7
13 schizophreniform disorder 11.3
14 psychotic disorder 11.1
15 neuroleptic malignant syndrome 11.1
16 darier disease 11.0
17 landau-kleffner syndrome 10.9
18 brain glioblastoma multiforme 10.8 COMT DAOA DISC1 DRD2 DRD3 DTNBP1
19 chronic conjunctivitis 10.8 COMT DAOA DISC1 DRD2 DRD3 DTNBP1
20 syngap1-related non-syndromic intellectual disability 10.7
21 hyperprolinemia, type i 10.7
22 social emotional agnosia 10.7
23 dopamine beta-hydroxylase deficiency 10.7
24 chromosome 15q13.3 microdeletion syndrome 10.7
25 chromosome 1q21.1 deletion syndrome 10.7
26 paraphilia disorder 10.7 COMT DISC1 DRD2 DRD3 HTR2A MTHFR
27 bipolar disorder 10.6
28 primary angle-closure glaucoma 10.6 COMT DAO DTNBP1 HTR2A NRG1
29 benign epilepsy with centrotemporal spikes 10.6 COMT DAOA DISC1 DRD2 HTR2A
30 chondrodysplasia lethal recessive 10.6 COMT DAOA NRG1 PRODH
31 delusional disorder 10.6
32 cytomegalic congenital adrenal hypoplasia 10.6 COMT DRD2 DRD3 HTR2A
33 cecal benign neoplasm 10.6 COMT DRD2 DRD3 HTR2A
34 retinoblastoma 10.6 COMT DRD2 DRD3 HTR2A
35 schizotypal personality disorder 10.6
36 rhinoscleroma 10.6 COMT DRD2 NRG1
37 teratoma with malignant transformation 10.6 DRD2 DRD3 HTR2A
38 microcephaly 13, primary, autosomal recessive 10.6 DRD2 DRD3 HTR2A MTHFR
39 pyromania 10.5 DRD2 DRD3 HTR2A
40 ellis-van creveld syndrome 10.5 COMT DRD2 DRD3 HTR2A
41 c8 deficiency, type ii 10.5 COMT DRD2 DRD3
42 preeclampsia/eclampsia 5 10.5 COMT DRD2 DRD3 HTR2A
43 hypertrophic olivary degeneration 10.5 COMT PRODH
44 basal cell carcinoma 3 10.5 COMT DRD2 HTR2A
45 hepatitis d 10.4 COMT DRD2 HTR2A
46 tardive dyskinesia 10.4
47 nephronophthisis 13 10.4 COMT HTR2A
48 neuronitis 10.3
49 sphenoorbital meningioma 10.3 DRD2 DRD3
50 mood disorder 10.2

Comorbidity relations with Schizophrenia via Phenotypic Disease Network (PDN): (show all 15)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Heart Disease Hypothyroidism
Iron Deficiency Anemia Paranoid Schizophrenia
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Tardive Dyskinesia

Graphical network of the top 20 diseases related to Schizophrenia:



Diseases related to Schizophrenia

Symptoms & Phenotypes for Schizophrenia

Symptoms by clinical synopsis from OMIM:

181500

Clinical features from OMIM:

181500 604906 603013

Human phenotypes related to Schizophrenia:

32 (show all 14)
id Description HPO Frequency HPO Source Accession
1 hypertelorism 32 HP:0000316
2 frontal bossing 32 HP:0002007
3 eeg abnormality 32 HP:0002353
4 hallucinations 32 HP:0000738
5 short stature 32 HP:0004322
6 ectopic kidney 32 HP:0000086
7 protruding ear 32 HP:0000411
8 schizophrenia 32 HP:0100753
9 flat occiput 32 HP:0005469
10 renal agenesis 32 HP:0000104
11 delusions 32 HP:0000746
12 social and occupational deterioration 32 HP:0007086
13 partially duplicated kidney 32 HP:0008738
14 short proximal phalanx of the 4th toe 32 HP:0100396

UMLS symptoms related to Schizophrenia:


fatigue, sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

GenomeRNAi Phenotypes related to Schizophrenia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.53 DRD2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.53 CHI3L1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.53 TAAR6
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.53 TAAR6
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.53 CHI3L1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.53 CHI3L1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 9.53 CHI3L1 DRD2 TAAR6
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-175 9.53 TAAR6
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.53 CHI3L1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.53 TAAR6
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.53 DRD2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.53 DRD2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.53 TAAR6
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-94 9.53 TAAR6

MGI Mouse Phenotypes related to Schizophrenia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.65 COMT DAO DISC1 DRD2 DRD3 DTNBP1
2 nervous system MP:0003631 9.32 DRD3 DTNBP1 MTHFR PRODH RTN4R SYN2

Drugs & Therapeutics for Schizophrenia

Drugs for Schizophrenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 687)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
4
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
5
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1 146939-27-7 60854
6
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
7
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1 5786-21-0 2818
8
Etomidate Approved Phase 4 33125-97-2 36339 667484
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
11
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
12
Reboxetine Approved, Investigational Phase 4,Phase 3,Phase 1 98769-81-4, 71620-89-8 123628 65856
13
Sulpiride Approved Phase 4,Phase 3,Phase 2,Phase 1 15676-16-1 5355
14 Moxonidine Approved Phase 4 75438-57-2 4810
15
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 54-11-5 942 89594
16
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2 249296-44-4 5310966
17
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1 52-86-8 3559
18
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
19
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 112111-43-0
20
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
21
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 10118-90-8 5281021
22
Chlorpromazine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-53-3 2726
23
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
24
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
25
Methyltestosterone Approved Phase 4 58-18-4 6010
26
Testosterone Approved, Investigational Phase 4 58-22-0 6013
27
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
28
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
29
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1 846-49-1 3958
30
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 75614-87-8, 51-45-6 774
31
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
32
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 439302 53477758
33
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
34
Perphenazine Approved Phase 4,Phase 3,Phase 2 58-39-9 4748
35
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 3404 5324346
36
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
37
Famotidine Approved Phase 4,Phase 2,Phase 3 76824-35-6 3325
38
Galantamine Approved Phase 4,Phase 2,Phase 3 357-70-0 9651 908828, 9651
39
Pimozide Approved Phase 4,Phase 3,Phase 2 2062-78-4 16362
40
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
41
Trifluoperazine Approved Phase 4,Phase 3 117-89-5 5566
42
Menthol Approved Phase 4 2216-51-5 16666
43
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1 50-36-2 5760 446220
44
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1 61869-08-7 43815
45
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
46
Methotrimeprazine Approved Phase 4,Phase 3,Phase 2 60-99-1 72287
47
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1 768-94-5 2130
48
Pramipexole Approved, Investigational Phase 4,Phase 3 104632-26-0 59868 119570
49
Mianserin Approved Phase 4,Phase 3 24219-97-4 4184
50
Mirtazapine Approved Phase 4,Phase 3 85650-52-8, 61337-67-5 4205

Interventional clinical trials:

(show top 50) (show all 2888)
id Name Status NCT ID Phase
1 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4
2 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
3 Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia Unknown status NCT00186771 Phase 4
4 A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia Unknown status NCT01490567 Phase 4
5 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4
6 Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Unknown status NCT02049021 Phase 4
7 Diabetes Prevention Program in Schizophrenia [DPPS] Unknown status NCT00182494 Phase 4
8 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4
9 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4
10 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4
11 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4
12 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4
13 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Unknown status NCT00802919 Phase 4
14 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4
15 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4
16 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4
17 Varenicline Adjunctive Treatment in Schizophrenia Unknown status NCT00492349 Phase 4
18 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4
19 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4
20 Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) Unknown status NCT01822418 Phase 4
21 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4
22 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4
23 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4
24 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4
25 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4
26 Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype Unknown status NCT01078870 Phase 4
27 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4
28 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4
29 Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning Unknown status NCT00937261 Phase 4
30 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4
31 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4
32 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4
33 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4
34 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4
35 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4
36 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4
37 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4
38 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
39 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4
40 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4
41 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4
42 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4
43 Ziprasidone vs Standard Therapy for Agitated Patients in the ED Unknown status NCT00786318 Phase 4
44 The Effects of Nicotine on Cognition in Schizophrenia Completed NCT00383747 Phase 4
45 A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics Completed NCT02712463 Phase 4
46 Assertive Community Treatment (ACT) in Schizophrenia Spectrum Disorders Completed NCT01081418 Phase 4
47 Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate Completed NCT02532842 Phase 4
48 Evaluation of Mirtazapine and Folic Acid for Schizophrenia: Completed NCT01263080 Phase 4
49 Risperidone Maintenance Treatment in Schizophrenia Completed NCT00848432 Phase 4
50 Folate Supplementation in Schizophrenia Completed NCT00249288 Phase 4

Search NIH Clinical Center for Schizophrenia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: schizophrenia

Genetic Tests for Schizophrenia

Genetic tests related to Schizophrenia:

id Genetic test Affiliating Genes
1 Schizophrenia 29 24 TAAR6
2 Schizophrenia 9 29
3 Schizophrenia 6 29

Anatomical Context for Schizophrenia

MalaCards organs/tissues related to Schizophrenia:

39
Brain, Cortex, Prefrontal Cortex, Testes, Cingulate Cortex, Eye, Temporal Lobe

Publications for Schizophrenia

Articles related to Schizophrenia:

(show top 50) (show all 6900)
id Title Authors Year
1
Examining methods, messengers and behavioural theories to disseminate physical activity information to individuals with a diagnosis of schizophrenia: a scoping review. ( 28084841 )
2017
2
Clinical Correlates of Treatment Response among Patients with Schizophrenia in a Tertiary Nigerian Hospital. ( 28529220 )
2017
3
5-HT1A C-1019G (rs6295) Predicts Aripiprazole Treatment Response Specifically for Cognitive and Depressive Symptoms in Schizophrenia. ( 28027114 )
2017
4
The impact of a TV report in schizophrenia stigma reduction: A quasi-experimental study. ( 28084154 )
2017
5
Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study. ( 28464965 )
2017
6
Judgment of moral and social transgression in schizophrenia. ( 28531645 )
2017
7
A Case-Control Study of the Association between Polymorphisms in the Fibrinogen Alpha Chain Gene and Schizophrenia. ( 28203040 )
2017
8
Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. ( 28528597 )
2017
9
The Effect of Cognitive Remediation Therapy on Social Skills in Institutionalized Elderly Patients with Schizophrenia. ( 28530532 )
2017
10
Concurrent validity of Indian Disability Evaluation and Assessment Scale with sociooccupational functioning scale in patients with schizophrenia. ( 28529369 )
2017
11
Socio-Demographic Characteristics, Partner Characteristics, Socioeconomic Variables, and Intimate Partner Violence in Women with Schizophrenia in South-South Nigeria. ( 28529219 )
2017
12
Surgical Management of Obesity Among People with Schizophrenia and Bipolar Disorder: a Systematic Review of Outcomes and Recommendations for Future Research. ( 28508277 )
2017
13
Predictors of long term use of psychiatric services of patients with recent-onset schizophrenia: 12A years follow-up. ( 28088223 )
2017
14
Impact of DRD2/ANKK1 and COMT Polymorphisms on Attention and Cognitive Functions in Schizophrenia. ( 28085950 )
2017
15
Effect of childhood trauma on cognitive functions in a sample of Chinese patients with schizophrenia. ( 28528230 )
2017
16
Aberrant spontaneous neural activity and correlation with evoked-brain potentials in first-episode, treatment-naA^ve patients with deficit and non-deficit schizophrenia. ( 28092779 )
2017
17
White matter connectivity disruptions in early and chronic schizophrenia. ( 28528586 )
2017
18
The Cost of Relapse in Schizophrenia. ( 28534254 )
2017
19
Association of the IFN-I^ (+874A/T) Genetic Polymorphism with Paranoid Schizophrenia in Tunisian Population. ( 27819519 )
2017
20
A Comparative Study Of Short Term Efficacy Of Aripiprazole And Risperidone In Schizophrenia. ( 28088913 )
2017
21
Altered Expression of ARP2/3 Complex Signaling Pathway Genes in Prefrontal Layer 3 Pyramidal Cells in Schizophrenia. ( 27523502 )
2017
22
GRIN3B missense mutation as an inherited risk factor for schizophrenia: whole-exome sequencing in a family with a familiar history of psychotic disorders. ( 28132660 )
2017
23
Downregulation of GNA13-ERK network in prefrontal cortex of schizophrenia brain identified by combined focused and targeted quantitative proteomics. ( 28214564 )
2017
24
Bipolar I disorder in remission vs. schizophrenia in remission: Is there a difference in burden? ( 27816846 )
2017
25
Representativeness of clinical PET study participants with schizophrenia: A systematic review. ( 28088727 )
2017
26
Short communication: Genetic association between schizophrenia and cannabis use. ( 28086176 )
2017
27
Genetic risk for schizophrenia and psychosis in Alzheimer disease. ( 28461698 )
2017
28
Hippocampal-prefrontal connectivity as a translational phenotype for schizophrenia. ( 28089652 )
2017
29
Long noncoding RNA as an indicator differentiating schizophrenia from major depressive disorder and generalized anxiety disorder in nonpsychiatric hospital. ( 28092449 )
2017
30
Increased serum G72 protein levels in patients with schizophrenia: a potential candidate biomarker. ( 27412497 )
2017
31
Mismatch negativity (MMN) to spatial deviants and behavioral spatial discrimination ability in the etiology of auditory verbal hallucinations and thought disorder in schizophrenia. ( 28532686 )
2017
32
Gender-Specific Associations between CHGB Genetic Variants and Schizophrenia in a Korean Population. ( 28332369 )
2017
33
Schizophrenia-like symptoms in a patient with Leigh syndrome. ( 28262162 )
2017
34
Identification of genetic loci shared between schizophrenia and the Big Five personality traits. ( 28533504 )
2017
35
An Association Between Functional Polymorphisms of the Interleukin 1 Gene Complex and Schizophrenia Using Transmission Disequilibrium Test. ( 28083609 )
2017
36
Association between ErbB4 single nucleotide polymorphisms and susceptibility to schizophrenia: A meta-analysis of case-control studies. ( 28225484 )
2017
37
Neuregulin-1 mutant Mice indicate motor and sensory deficits, indeed few references for schizophrenia endophenotype model. ( 28089851 )
2017
38
Shared abnormality of white matter integrity in schizophrenia and bipolar disorder: A comparative voxel-based meta-analysis. ( 28082140 )
2017
39
Reelin (RELN) DNA methylation in the peripheral blood of schizophrenia. ( 28086126 )
2017
40
Association of Polymorphisms of the Receptor for Advanced Glycation Endproducts Gene with Schizophrenia in a Han Chinese Population. ( 28373983 )
2017
41
Meta-analysis of polymorphism rs6311 and rs6313 in the 5-HT2AR gene and schizophrenia. ( 27598719 )
2017
42
Phenotypic continuum between autism and schizophrenia: Evidence from the Movie for the Assessment of Social Cognition (MASC). ( 28089135 )
2017
43
Brain-Derived Neurotrophic Factor Expression in Individuals With Schizophrenia and Healthy Aging: Testing the Accelerated Aging Hypothesis of Schizophrenia. ( 28534294 )
2017
44
Following Instructions in Patients With Schizophrenia: The Benefits of Actions at Encoding and Recall. ( 28531307 )
2017
45
Wisconsin Card Sorting Test performance impairment in schizophrenia: An Indian study report. ( 28529366 )
2017
46
Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls. ( 28091349 )
2017
47
Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. ( 28086761 )
2017
48
HDAC1 links early life stress to schizophrenia-like phenotypes. ( 28533418 )
2017
49
Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study. ( 28087270 )
2017
50
Towards the recovery of a sense of self: An interpretative phenomenological analysis of patients' experience of body-oriented psychotherapy for schizophrenia. ( 28532254 )
2017